Eli Lilly and Co., of Indianapolis, said basal insulin peglispro (BIL) demonstrated a statistically significant lower hemoglobin A1c (HbA1c) compared with Lantus (insulin glargine, Sanofi SA) at 26 weeks and 52 weeks, respectively, in the IMAGINE-1 and IMAGINE-3 phase III trials in patients with type 1 diabetes.